Anti-infliximab antibody status and its relation to clinical response in psoriatic patients: A pilot study

Journal of Dermatology

Volumn 37, Issue 8, 2010, Pages 708-713

  Adişen, Esra ^a   Aral, Arzu ^a   Aybay, Cemalettin ^a   Gürer, Mehmet Ali ^a  

^a GAZI UNIVERSITY   (Turkey)

Author keywords

antibodies to infliximab; clinical response; infliximab; loss of efficacy

Indexed keywords

ANTIBODY; CORTICOSTEROID; INFLIXIMAB;

ADULT; AGED; ANTIBODY PRODUCTION; ARTICLE; CLINICAL ARTICLE; CORTICOSTEROID THERAPY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; PILOT STUDY; PSORIASIS SEVERITY INDEX; PSORIASIS VULGARIS; PUSTULAR PSORIASIS; TREATMENT RESPONSE;

ADRENAL CORTEX HORMONES; AGED; ANTIBODIES; ANTIBODIES, MONOCLONAL; DERMATOLOGIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PSORIASIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 77954893886     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/j.1346-8138.2010.00882.x     Document Type: Article

References (26)

1. Gottlieb AB, Chaudhari U, Mulcahy LD, Li S, Dooley LT, Baker DG. Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis. J Am Acad Dermatol 2003 486 : 829 835.
2. Menter A, Feldman SR, Weinstein GD et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2007 56 : 1 15.
3. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001 357 (9271 1842 1847.
4. Reich K, Nestle FO, Papp K et al. Infliximab induction and maintenance therapy for moderate-to severe psoriasis: a phase III, multicentre, double blind trial. Lancet 2005 366 : 1367 1374.
5. Nast A, Kopp IB, Augustin M et al. Deutsche Dermatologische Gesellschaft (DDG); Berufsverband Deutscher Dermatologen (BVDD). Evidence-based (S3) guidelines for the treatment of psoriasis vulgaris. J Dtsch Dermatol Ges 2007 5 : 1 119.
6. Baert F, De Vos M, Louis E, Vermeire S Belgian IBD Research Group. Immunogenicity of infliximab: how to handle the problem? Acta Gastroenterol Belg 2007 70 : 163 170.
7. Cheifetz A, Mayer L. Monoclonal antibodies, immunogenicity, and associated infusion reactions. Mt Sinai J Med 2005 72 : 250 256.
8. Pendley C, Schantz A, Wagner C. Immunogenicity of therapeutic monoclonal antibodies. Curr Opin Mol Ther 2003 5 : 172 179.
9. Aybay C, Ozel S, Aybay C. Demonstration of specific antibodies against infliximab induced during treatment of a patient with ankylosing spondylitis. Rheumatol Int 2006 26 : 473 480.
10. Maini RN, Breedveld FC, Kalden JR et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998 41 : 1552 1563.
11. Wolbink GJ, Vis M, Lems W et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 2006 54 : 711 715.
12. de Vries MK, Wolbink GJ, Stapel SO et al. Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation. Ann Rheum Dis 2007 66 : 1252 1254.
13. Hanauer SB, Wagner CL, Bala M et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004 2 : 542 543.
14. Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial. Lancet 2002 359 : 1541 1549.
15. Sandborn W. Preventing antibodies to infliximab in patients with Crohn's disease: optimize not immunize. Gastroenterology 2003 124 : 1140 1145.
16. Rutgeerts P, Feagan BG, Lichtenstein GR et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004 126 : 202 213.
17. Martínez-Borra J, López-Larrea C, González S et al. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease. Am J Gastroenterol 2002 97 : 2350 2356.
18. Haraoui B, Cameron L, Ouellet M, White B. Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response. J Rheumatol 2006 33 : 31 36.
19. Van der Laken CJ, Voskuyl AE, Roos JC et al. Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis. Ann Rheum Dis 2007 66 : 253 256.
20. Gottlieb AB, Evans R, Li S et al. Infliximab induction therapy for patients with severe plaque type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004 51 : 534 542.
21. van der Bijl AE, Breedveld FC, Antoni CE et al. An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status. Clin Rheumatol 2008 27 : 1021 1028. [Epub ahead of print]
22. Ainsworth MA, Bendtzen K, Brynskov J. Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease. Am J Gastroenterol 2008 103 : 944 948.
23. Baert F, Noman M, Vermeire S et al. Influence of immunogenicity on the longterm efficacy of infliximab in Crohn's disease. N Engl J Med 2003 348 : 601 608.
24. Forero A, Meredith RF, Khazaeli MB et al. A novel monoclonal antibody design for radioimmunotherapy. Cancer Biother Radiopharm 2003 18 : 751 759.
25. Miele E, Markowitz JE, Mamula P, Baldassano RN. Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab. J Pediatr Gastroenterol Nutr 2004 38 : 502 508.
26. Vermeire S, Noman M, Van Assche G et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 2007 56 : 1226 1231.